Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures.

At Dexcom (Nasdaq:DXCM), one of the leaders in continuous glucose monitoring (CGM), innovation continues to roll on.

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dexcom CEO Kevin Sayer shared new data on the company’s ...

LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. A warning letter posted Tuesday by the Food and Drug ...

The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin. The device is similar to existing prescription CGMs. Users pair the ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

Roughly 1.25 million Americans have Type 1 diabetes, so chances are you know somebody whose pancreas is taking the world’s longest lunch break. That person may be you. As it happens, there has never ...

DexCom, Inc. ( NASDAQ: DXCM) Baird Global Healthcare Conference 2025 September 10, 2025 2:00 PM EDT Next presentation this afternoon is from DexCom, a leader in developing and commercializing ...

Dexcom, the San Diego-based maker of continuous glucose monitors for diabetes patients and prediabetics, announced Wednesday ...